Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4.

Here, we report on the synthesis, enzymatic stability, and antitumor activity of novel bioconjugates containing the chemotherapeutic agent daunorubicin attached through an oxime bond to various gonadotropin-releasing hormone-III (GnRH-III) derivatives. In order to increase the enzymatic stability of the bioconjugates (in particular against chymotrypsin), (4)Ser was replaced by N-Me-Ser or Lys(Ac). A compound in which (4)Lys was not acetylated was also prepared, with the aim of investigating the influence of the free ε-amino group on the biochemical properties. The in vitro cytostatic effect of the bioconjugates was determined on MCF-7 human breast, HT-29 human colon, and LNCaP human prostate cancer cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Their stability/degradation (1) in human serum, (2) in the presence of rat liver lysosomal homogenate, and (3) in the presence of digestive enzymes (trypsin, chymotrypsin, and pepsin) was analyzed by liquid chromatography in combination with mass spectrometry. The results showed that (1) all synthesized bioconjugates had in vitro cytostatic effect, (2) they were stable in human serum at least for 24 h, and (3) they were hydrolyzed in the presence of lysosomal homogenate. All compounds were stable in the presence of (1) pepsin and (2) trypsin (except for the (4)Lys containing bioconjugate). In the presence of chymotrypsin, all bioconjugates were digested; the degradation rate strongly depending on their structure. The bioconjugates in which (4)Ser was replaced by N-Me-Ser or Lys(Ac) had the highest enzymatic stability, making them potential candidates for oral administration. In vivo tumor growth inhibitory effect of two selected bioconjugates was evaluated on orthotopically developed C26 murine colon carcinoma bearing mice. The results indicated that the compound containing Lys(Ac) in position 4 had significantly higher antitumor activity than the parent bioconjugate.

[1]  G. Mező,et al.  In-vivo antitumour effect of daunorubicin–GnRH-III derivative conjugates on colon carcinoma-bearing mice , 2012, Anti-cancer drugs.

[2]  G. Spyroulias,et al.  Enzymatic stability, solution structure, and antiproliferative effect on prostate cancer cells of leuprolide and new gonadotropin-releasing hormone peptide analogs. , 2011, Biopolymers.

[3]  G. Mező,et al.  In vitro degradation and antitumor activity of oxime bond-linked daunorubicin–GnRH-III bioconjugates and DNA-binding properties of daunorubicin–amino acid metabolites , 2011, Amino Acids.

[4]  G. Mező,et al.  Receptor-mediated tumor targeting based on peptide hormones , 2010, Expert opinion on drug delivery.

[5]  G. Mező,et al.  Luteinizing hormone-releasing hormone antagonists , 2009, Expert opinion on therapeutic patents.

[6]  M. Przybylski,et al.  Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug. , 2009, Bioconjugate chemistry.

[7]  G. Mező,et al.  New derivatives of GnRH as potential anticancer therapeutic agents. , 2008, Current medicinal chemistry.

[8]  Adam J Pawson,et al.  Gonadotropin-releasing hormone analog structural determinants of selectivity for inhibition of cell growth: support for the concept of ligand-induced selective signaling. , 2008, Molecular endocrinology.

[9]  B. Glasgow,et al.  Site-directed circular dichroism of proteins: 1Lb bands of Trp resolve position-specific features in tear lipocalin. , 2008, Analytical biochemistry.

[10]  O. Csuka,et al.  Structure, enzymatic stability and antitumor activity of sea lamprey GnRH-III and its dimer derivatives , 2007, Peptides.

[11]  J. Seprődi,et al.  Structure–activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs , 2007, Peptides.

[12]  A. Schally,et al.  Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone , 2007, Nature Clinical Practice Endocrinology &Metabolism.

[13]  R. Murphy,et al.  Is lGnRH‐III the most potent GnRH analog containing only natural amino acids that specifically inhibits the growth of human breast cancer cells? , 2006, Journal of peptide science : an official publication of the European Peptide Society.

[14]  Valérie Campagna-Slater,et al.  Dissociation reactions of protonated anthracycline antibiotics following electrospray ionization-tandem mass spectrometry , 2006 .

[15]  R. Millar.  GnRHs and GnRH receptors. , 2005, Animal reproduction science.

[16]  R. Murphy,et al.  Importance of the central region of lamprey gonadotropin-releasing hormone III in the inhibition of breast cancer cell growth , 2005, Peptides.

[17]  A. Schally,et al.  Chemotherapy targeted to cancers through tumoral hormone receptors , 2004, Trends in Endocrinology & Metabolism.

[18]  M. Motta,et al.  The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans , 2003, Frontiers in Neuroendocrinology.

[19]  A. Schally,et al.  New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. , 2003, Life sciences.

[20]  M. Koppán,et al.  Lamprey Gonadotropin Hormone‐Releasing Hormone‐III has No Selective Follicle‐Stimulating Hormone‐Releasing Effect In Rats , 2002, Journal of neuroendocrinology.

[21]  W. Schaaper,et al.  The role of the individual amino acids of a GnRH-tandem-dimer peptide used as an antigen for immunocastration of male piglets determined with systematic alanine replacements. , 2001, Vaccine.

[22]  M Mezei,et al.  Conformational Space Comparison of GnRH and lGnRH-III using Molecular Dynamics, Cluster Analysis and Monte Carlo Thermodynamic Integration , 2001, Journal of biomolecular structure & dynamics.

[23]  R. Murphy,et al.  Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Murphy,et al.  Direct anticancer activity of gonadotropin-releasing hormone-III. , 2009, The journal of peptide research : official journal of the American Peptide Society.

[25]  R. Murphy,et al.  Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships. , 1997, Journal of medicinal chemistry.

[26]  S. Lovas,et al.  Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain. , 1993, Endocrinology.

[27]  C. Nichols,et al.  Stabilization of the N-terminal residues of luteinizing hormone-releasing hormone agonists and the effect on pharmacokinetics. , 1992, Journal of medicinal chemistry.

[28]  A. Kastin,et al.  Dissociation of effects of LH-RH analogs on pituitary regulation and reproductive behavior , 1980, Pharmacology Biochemistry and Behavior.